Norges Bank
DNTH icon

Norges Bank’s Dianthus Therapeutics DNTH Stock Holding History

Norges Bank’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-447
Closed -$86K – 2122
2018
Q3 		$86K Sell
447
-4,241
-90% -$893K ﹤0.01% 2126
2018
Q2 		$1.01M Buy
+4,688
New +$1.06M ﹤0.01% 2066

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Norges Bank's DNTH Position: Q4 2018 in Review

Norges Bank sold out of Dianthus Therapeutics (DNTH) in Q4 2018, closing a stake of 447 shares — an estimated $86K sold.

Norges Bank first reported a position in DNTH in Q2 2018 and held it in 2 quarters. The position peaked at $1.01M in Q2 2018. 54 funds tracked by Wall St. Rank hold DNTH as of Q4 2018.

  • Norges Bank reported no remaining Dianthus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Norges Bank sold 447 Dianthus Therapeutics shares in Q4 2018, an estimated $86K.
  • Norges Bank first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 2 quarters.
  • Norges Bank's Dianthus Therapeutics position peaked at $1.01M in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2018.

Based on Norges Bank's 13F filing for Q4 2018, filed 8 Feb 2019.